Statin Use for Primary Cardiovascular Disease Prevention Is Low in Inflammatory Arthritis

Kuriya, Bindee; Akhtari, Shadi; Movahedi, Masoud; Udell, Jacob A.; Lawler, Patrick R.; Farkouh, Michael E.; Keystone, Edward; Hanneman, Kate; Nguyen, Elsie T.; Harvey, Paula; Eder, Lihi

doi:10.1016/j.cjca.2022.04.002

Cited by 4 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CVDs remain to be the leading causes of death in patients with RA according to a newly reported cohort study in Australia. 22 To improve the risk evaluation of CVDs in RA, Kuriya et al 23 estimated cardiac and lipid biomarkers in patients with RA and no diagnosis of CVDs. The results showed that abnormalities in biomarkers are already common in these patients, even in those with well-controlled arthritis.…”

Section: Cardiovascular Diseases (Cvds)mentioning

confidence: 99%

New insights into the pathogenesis and management of rheumatoid arthritis

Jin

Zeng

et al. 2022

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

Over the past few decades, understanding of the pathogenesis of rheumatoid arthritis (RA) has improved substantially. Insights into the cellular and molecular mechanisms involved in RA have enabled the discovery of new therapeutic targets and led to the development of biologics and targeted synthetic disease‐modifying antirheumatic drugs. In parallel with the improvement in therapies, the evolution of strategies in the management of RA has also contributed considerably to better outcomes in patients. Major changes include the development of disease activity measures, formulation of the treat‐to‐target principles as well as increased attention to comorbidities. The presence of comorbidities such as cardiovascular diseases may increase the mortality of RA patients, affect their treatment strategies and result in worse outcomes. Therefore, prevention and management of certain high‐risk comorbidities have become increasingly important in the long‐term treatment of RA. In this study, we summarized new insights into the pathogenesis and management of rheumatoid arthritis and associated comorbidities, with a special focus on the 2021 update of the American College of Rheumatology (ACR) guideline for RA and key reports presented at the 2021 ACR convergence.

show abstract

Section: Cardiovascular Diseases (Cvds)mentioning

confidence: 99%

New insights into the pathogenesis and management of rheumatoid arthritis

Jin

Zeng

et al. 2022

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

show abstract

“…6 The results of the study by Kuriya et al uncover a substantial unmet need and opportunity to intervene for patients with inflammatory arthritis at increased risk of ASCVD with guideline-recommended therapies. 5 Furthermore, primary treatment of rheumatoid arthritis itself to lower disease activity ordideallydremission concurrently lowers risk of Canadian Journal of Cardiology 38 (2022) 1138e1140 ASCVD driven by systemic inflammation, 7 especially with tumour necrosis factor inhibitors. 8 Nevertheless, the persistent risk of MACE in patients with well-controlled rheumatoid arthritis must simultaneously be addressed by treating conventional ASCVD risk factors.…”

mentioning

confidence: 99%